Unknown

Dataset Information

0

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.


ABSTRACT: According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug-drug interactions (DDIs) and may offer an alternative to dedicated clinical trials. This study provides whole-body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology (OSP) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical DDI studies. In total, 112 studies were used for model development and 57 studies for DDI prediction. 93% of the predicted area under the plasma concentration-time curve (AUC) ratios and 94% of the peak plasma concentration (Cmax ) ratios are within twofold of the observed values. This study lays a cornerstone for the qualification of the OSP platform with regard to reliable PBPK predictions of enzyme-mediated and transporter-mediated DDIs during model-informed drug development. All presented models are provided open-source and transparently documented.

SUBMITTER: Hanke N 

PROVIDER: S-EPMC6202474 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Hanke Nina N   Frechen Sebastian S   Moj Daniel D   Britz Hannah H   Eissing Thomas T   Wendl Thomas T   Lehr Thorsten T  

CPT: pharmacometrics & systems pharmacology 20180907 10


According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug-drug interactions (DDIs) and may offer an alternative to dedicated clinical trials. This study provides whole-body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology (OSP) Suite. All models w  ...[more]

Similar Datasets

| S-EPMC9292161 | biostudies-literature
| S-EPMC4860537 | biostudies-other
| S-EPMC6885506 | biostudies-literature
| S-EPMC5980546 | biostudies-literature
| S-EPMC10994486 | biostudies-literature
| 2729773 | ecrin-mdr-crc
| S-EPMC2712435 | biostudies-literature
| S-EPMC3745465 | biostudies-literature
| S-EPMC3774043 | biostudies-literature
| S-EPMC6362450 | biostudies-literature